ProCE Banner Activity

How Data From IAS 2019 on Dual Therapy May Soon Affect ART Guidelines

Conference Coverage
Clinical Thought
Updated first-line and switch data reinforce the noninferiority of DTG/3TC compared with 3-drug regimens. How will these results affect practice? Here’s my take.

Released: August 20, 2019

Expiration: August 18, 2020

No longer available for credit.

Share

Faculty

Jürgen K. Rockstroh

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Educational grant provided by:

Gilead

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner

Faculty Disclosure

Primary Author

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Gilead Sciences, Janssen, Merck, and ViiV Healthcare and funds for non-CME/CE services from Gilead Sciences, Janssen, Merck, and ViiV Healthcare.